ReviewFrontiers in medicine2025
Ginsenoside potential targeting hypoxia-inducible factor-1α as promising therapeutics for cancer: a review.
Review in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ginseng is a Chinese medicine known for its tonic effect. Numerous studies have shown that ginseng exerts therapeutic effects on cancer cells. Hypoxia-inducible factor-1α (HIF-1α) is an important transcriptional regulator in response to a hypoxic environment and is crucial in the adaptation of tumor cells to the hypoxic environment. During tumor growth, HIF-1α regulates the activity of various transcription factors and their downstream molecules by modulating various biological processes, including cell proliferation, growth, angiogenesis, and metastasis. Therefore, high HIF-1α expression may be closely associated with poor prognosis in patients with various solid tumors. Pharmacological targeting of HIF-1α is considered a therapeutic strategy for cancer treatment. To investigate the molecular mechanism of ginseng's effect on cancer through HIF-1α, a more detailed and in-depth analysis is needed. In this review, we present ginseng as a HIF-1α inhibitor that can inhibit tumor development
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.